Asuragen Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 144

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $321M

Asuragen General Information

Description

Manufacturer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases. The company presents a wide range of kits and assays for genetic sequencing as well as cancer monitoring, enabling the medical community to enhance treatment outcomes through accurate data.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Biotechnology
Parent Company
Corporate Office
  • 2150 Woodward Street
  • Suite 100
  • Austin, TX 78744
  • United States
+1 (877) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Asuragen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 06-Apr-2021 $321M 000.00 00000 Completed Generating Revenue
7. Debt - PPP 27-Apr-2020 00.000 000.00 Completed Generating Revenue
6. Later Stage VC (Series C) 20-Mar-2013 00.00 000.00 00000 Completed Generating Revenue
5. Grant 30-Mar-2012 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 11-Aug-2011 000 000.00 000.00 Completed Generating Revenue
3. Grant 08-Oct-2008 00.00 000.00 Completed Startup
2. Early Stage VC (Series B) 10-Dec-2007 $18.5M $67.4M 000.00 Completed Startup
1. Early Stage VC (Series A) 01-Jun-2006 $48.9M $48.9M 000.00 Completed Startup
To view Asuragen’s complete valuation and funding history, request access »

Asuragen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A 48,895,000 $0.001000 $1 $1 1x $1 55.48%
To view Asuragen’s complete cap table history, request access »

Asuragen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases.
Diagnostic Equipment
Austin, TX
144 As of 2021
000.00
00000 0000-00-00
000000&0 000.00

000000

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000 000000000
Cambridge, MA
0000 As of 0000
00000
00.000 0000-00-00
00000000000

000000

liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupt
0000000000 000000000
San Diego, CA
0000 As of 0000
00.000
0000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Asuragen Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Foundation Medicine Formerly VC-backed Cambridge, MA 0000 00000 00000000000
Illumina Formerly VC-backed San Diego, CA 0000 00.000 0000 00.000
Gene By Gene Formerly Accelerator/Incubator backed Houston, TX 00 000000&0
Cisbio Bioassays Formerly PE-Backed Codolet, France 000 000000&0
Empire Genomics Private Equity-Backed Williamsville, NY 00 00.000 000000000000 00.000
You’re viewing 5 of 13 competitors. Get the full list »

Asuragen Patents

Asuragen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210189384-A1 Methods and compositions for amplicon concatenation Pending 26-Nov-2019 00000000000
US-20200140923-A1 Methods of rna amplification Active 19-Jan-2017 000000000
US-11236384-B2 Methods of rna amplification Active 19-Jan-2017 000000000 0
US-20200048696-A1 Methods for nucleic acid size detection of repeat sequences Active 03-Nov-2015 0000000000
US-20170121763-A1 Methods for nucleic acid size detection of repeat sequences Inactive 03-Nov-2015 C12Q1/6858
To view Asuragen’s complete patent history, request access »

Asuragen Board Members (13)

Name Representing Role Since
David Sargent Self Board Member 000 0000
Deval Lashkari Ph.D Telegraph Hill Partners Board Member 000 0000
Matthew Crawford PTV Healthcare Capital Board Member 000 0000
You’re viewing 3 of 13 board members. Get the full list »

Asuragen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asuragen Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cancer Prevention and Research Institute of Texas Government 000 0000 000000 0
Growth Capital Fund Venture Capital Minority 000 0000 000000 0
Merck Global Health Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
PTV Healthcare Capital Venture Capital Minority 000 0000 000000 0
Southwest Middle Market M&A Merchant Banking Firm Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Asuragen Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Mirna Therapeutics 01-Jan-2009 00000 0000 000 Biotechnology 0000000 0
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Biotechnology 0000000 0
To view Asuragen’s complete investments history, request access »

Asuragen Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
Mirna Therapeutics 01-Jan-2009 00000 00000 00 000 Completed
  • 00000000
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Completed
To view Asuragen’s complete exits history, request access »

Asuragen FAQs

  • When was Asuragen founded?

    Asuragen was founded in 2005.

  • Who is the founder of Asuragen?

    Matthew Winkler Ph.D is the founder of Asuragen.

  • Where is Asuragen headquartered?

    Asuragen is headquartered in Austin, TX.

  • What is the size of Asuragen?

    Asuragen has 144 total employees.

  • What industry is Asuragen in?

    Asuragen’s primary industry is Diagnostic Equipment.

  • Is Asuragen a private or public company?

    Asuragen is a Private company.

  • What is the current valuation of Asuragen?

    The current valuation of Asuragen is 00000.

  • What is Asuragen’s current revenue?

    The current revenue for Asuragen is 00000.

  • How much funding has Asuragen raised over time?

    Asuragen has raised $79.9M.

  • Who are Asuragen’s investors?

    Cancer Prevention and Research Institute of Texas, Growth Capital Fund, Merck Global Health Innovation Fund, PTV Healthcare Capital, and Southwest Middle Market M&A are 5 of 7 investors who have invested in Asuragen.

  • Who are Asuragen’s competitors?

    Foundation Medicine, Illumina, Gene By Gene, Cisbio Bioassays, and Empire Genomics are some of the 13 competitors of Asuragen.

  • When was Asuragen acquired?

    Asuragen was acquired on 06-Apr-2021.

  • Who acquired Asuragen?

    Asuragen was acquired by Bio-Techne.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »